Department of Clinical Genetics and Cardiology and VASCERN MSA European Reference Centre, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
Eur J Med Genet. 2022 Sep;65(9):104557. doi: 10.1016/j.ejmg.2022.104557. Epub 2022 Jun 30.
Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic disorder clinically characterized by vascular, intestinal and uterine fragility and caused by heterozygous pathogenic variants in the COL3A1 gene. Management of patients with vEDS is difficult due to the unpredictability of the events and clear recommendations on the care of adults and children with vEDS are lacking. Therefore, we aimed to collect data on the current strategy of surveillance and monitoring of vEDS patients by expert centers in continental Europe and Great Britain, as a first step towards a consensus statement. A survey on the clinical management of vEDS was sent to all members of the Medium Sized Artery (MSA) Working Group of the European Reference Network for Rare Vascular Diseases (VASCERN) and other expert centers. All experts endorse the importance of monitoring patients with vEDS. Despite the absence of evidence based guidelines monitoring is considered in almost all countries, but screening intervals and modalities used for monitoring may differ among centers. There is a need for more prospective multicenter studies to define proper guidelines.
血管型埃勒斯-当洛斯综合征(vEDS)是一种罕见的遗传性疾病,临床上以血管、肠道和子宫脆弱为特征,由 COL3A1 基因的杂合致病性变异引起。由于事件的不可预测性,vEDS 患者的管理较为困难,且目前尚缺乏针对 vEDS 成人和儿童护理的明确建议。因此,我们旨在通过欧洲大陆和英国的专家中心收集有关 vEDS 患者监测和监测的当前策略数据,作为达成共识声明的第一步。一项关于 vEDS 临床管理的调查已发送给欧洲罕见血管疾病参考网络(VASCERN)中型动脉(MSA)工作组的所有成员以及其他专家中心。所有专家都认为监测 vEDS 患者非常重要。尽管缺乏循证指南,但几乎所有国家都认为有必要进行监测,但监测的筛查间隔和方式可能因中心而异。需要更多的前瞻性多中心研究来制定适当的指南。